S&P Futures
5,886.00 -6.50 (-0.11%) Dow Futures
43,037.00 -132.00 (-0.31%) Nasdaq Futures
20,512.25 -29.75 (-0.14%) Russell 2000 Futures
2,244.10 -2.10 (-0.09%) Crude Oil
72.24 +0.15 (+0.21%) Gold
2,757.80 -2.00 (-0.07%)
Phio Pharmaceuticals Corp. (PHIO)
After hours:
| Previous Close | 3.1200 |
| Open | 3.1600 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 3.0401 - 3.2900 |
| 52 Week Range | 2.4000 - 18.8100 |
| Volume | |
| Avg. Volume | 75,185 |
| Market Cap | 2.694M |
| Beta (5Y Monthly) | 1.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -16.1300 |
| Earnings Date | Nov 07, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.00 |
NewsfileCorrection to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. M
NewsfilePhio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series
Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. M
